Highlights of recent faculty research.

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-Cell lymphoma in the United States.

Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, Cheng P, Ramsey SD

Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health

Watkins D, Yamey G, Schäferhoff M, Adeyi O, Alleyne G, Alwan A, Berkley S, Feachem R, Frenk J, Ghosh G, Goldie SJ, Guo Y, Gupta S, Knaul F, Kruk M, Nugent R, Ogbuoji O, Qi J, Reddy S, Saxenian H, Soucat A, Jamison DT, Summers LH